{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:30:45Z","timestamp":1787841045362,"version":"build-2784847793"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,14]],"date-time":"2020-11-14T00:00:00Z","timestamp":1605312000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background\/Objective:<\/jats:title>\n                    <jats:p>Myelodysplastic syndrome (MDS) is a clonal disorder of hematopoietic stem cells, characterized by ineffective hematopoiesis, peripheral cytopenias along with hypercellularity of the bone marrow, and marked dysplastic features. Establishing MDS diagnosis is difficult due to nonspecific clinical presentation and imprecise morphological criteria. In anticipation to improve the diagnostic approach in this field, we aimed to characterize the clinical and morphological features of patients presented with cytopenias with a special focus on MDS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We comprehensively reviewed all medical record of patients who were referred to the hematology laboratory at KFSH-RC, Riyadh, Saudi Arabia, between January 2009 and March 2016 for evaluation of bone marrow aspirates and trephine biopsies due to severe and persistent cytopenia(s) to rule out MDS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 183 patients, 155 adult and 28 pediatric, were identified. In the adult group, MDS was diagnosed in 82 (52.9%) patients, with a male-to-female (M:F) ratio of 1.6:1 and mean age at diagnosis of 50 years. According to the World Health Organization (WHO) 2017 criteria, MDS subtypes were as follows: MDS with single lineage dysplasia (SLD, 5%), MDS with ring sideroblasts and SLD (MDS-RS-SLD 7%), MDS with multilineage dysplasia (MDS-MLD 21%), MDS with deletion of chromosome 5q (MDS del(5q), 2%), MDS unclassifiable (MDS-U7%), hypoplastic MDS (h-MDS 4%), MDS with excess blasts-1 (MDS-EB1, 20%), MDS with excess blasts-2 (MDS- EB2, 28%), and therapy-related MDS (6%). Laboratory and morphological features were described. In both groups, cytogenetic abnormalities were classified according to the Revised International Prognostic Scoring System cytogenetic risk groups. In adults, the dominating cytogenetic abnormalities were monosomy 5 and monosomy 7 seen in 20.7% and 24.4% of patients, respectively. Peripheral cytopenia not due to MDS was diagnosed in 54 (34.8%) patients, with a mean age of 43 years and M:F ratio of 1:1. The cause of these cytopenias were as follows: bone marrow failure (BMF, 22%), peripheral destruction (20%), drug induced (20%), anemia of chronic disease (16%), B12 deficiency (7%), infection (7%), paroxysmal nocturnal hemoglobinuria (4%), idiopathic cytopenia of undetermined significance (2%), and idiopathic dysplasia of undetermined significance (2%). A definite diagnosis of MDS was not possible in 19 patients due to insufficient clinical data. In the pediatric group, MDS was diagnosed in 14\/28 (50%) patients, with M:F ratio of 1.8:1 and mean age at diagnosis of 4 years. MDS subtypes (WHO 2017) in 14 patients were as follows: refractory cytopenia of childhood (RCC, 42.8%), MDS-EB1 (42.8%), and MDS-EB2 (14.2%). Laboratory and morphological features were described. The prevalent cytogenetic abnormality was monosomy 7 in six\/14 (42.8%) patients. Cytopenias due to other causes were diagnosed in eight\/28 patients (28.5%), with a mean age of 6.5 years and M:F ratio of 1.6:1. The causes of non-MDS related cytopenia were: congenital BMF (4 patients), peripheral destruction (2 patients), immune deficiency (1 patient), and viral infection (1 patient). A definite diagnosis of MDS could not be made in six\/28 (21.4%) patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>MDS is the cause of cytopenia in a significant number of patients referred for evaluation of cytopenias, appears at younger age, and tends to be more aggressive than that reported in international studies. Anemia, dysplastic neutrophils in the peripheral blood, and dysplastic megakaryocytes in the bone marrow trephine biopsy are the most reliable features in distinguishing MDS from other alternative diagnoses.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1016\/j.hemonc.2020.11.001","type":"journal-article","created":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T21:08:08Z","timestamp":1605733688000},"page":"39-44","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Spectrum of Myelodysplastic Syndrome in Patients Evaluated for Cytopenia(s). A Report from a Reference Centre in Saudi Arabia"],"prefix":"10.4103","volume":"15","author":[{"given":"Nour","family":"AlMozain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayman","family":"Mashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qasem","family":"Alneami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal","family":"Al-Omran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasir","family":"Bakshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek","family":"Owaidah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salem","family":"Khalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitham","family":"Khogeer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrukh","family":"Hashmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suleimman","family":"Al-Sweedan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randa","family":"AlNounou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-6-20241211","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1182\/blood-2016-03-657379","article-title":"Introduction to a review series: the 2016 revision of the WHO classification of tumors of hematopoietic and lymphoid tissues","volume":"127","author":"Cazzola","year":"2016","journal-title":"Blood"},{"key":"R2-6-20241211","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1093\/jnci\/djn349","article-title":"Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys","volume":"100","author":"Sekeres","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"R3-6-20241211","doi-asserted-by":"crossref","first-page":"5358","DOI":"10.1200\/JCO.2006.07.5598","article-title":"Myelodysplastic syndromes in patients younger than age 50","volume":"24","author":"Kuendgen","year":"2006","journal-title":"J Clin Oncol"},{"key":"R4-6-20241211","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1046\/j.1365-2141.0000.d01-1480.x","article-title":"Myelodysplastic syndromes in childhood: report of 49 patients from a French multicentre study","volume":"92","author":"Bader-Meunier","year":"1996","journal-title":"Br J Haematol"},{"key":"R5-6-20241211","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1007\/s11899-015-0269-y","article-title":"Incidence and burden of the myelodysplastic syndromes","volume":"10","author":"Cogle","year":"2015","journal-title":"Curr Hematol Malig Rep"},{"key":"R6-6-20241211","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2188\/jea.JE20140042","article-title":"Incidence of myelodysplastic syndrome in Japan","volume":"24","author":"Chihara","year":"2014","journal-title":"J Epidemiol"},{"key":"R7-6-20241211","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1159\/000226286","article-title":"Primary myelodysplastic syndrome in Jordan: a single-centre experience","volume":"18","author":"Awidi","year":"2009","journal-title":"Med Princ Pract"},{"key":"R8-6-20241211","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1080\/10428190701377063","article-title":"The clinical, haematological and morphological profile of patients with myelodysplastic syndromes: A single institution experience from Turkey","volume":"48","author":"Demirkan","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"R9-6-20241211","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/j.1365-2257.2006.00823.x","article-title":"Pattern of haematological diseases diagnosed by bone marrow examination in Yemen: a developing country experience","volume":"28","author":"Al-Ghazaly","year":"2006","journal-title":"Clin Lab Haematol"},{"key":"R10-6-20241211","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jare.2018.02.002","article-title":"Cytogenetic features in primary myelodysplastic syndrome Egyptian patients","volume":"10","author":"Elnahass","year":"2018","journal-title":"J Adv Res"},{"key":"R12-6-20241211","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.leukres.2005.07.005","article-title":"Young age MDS: Differences between Western and Eastern countries","volume":"30","author":"Paydas","year":"2006","journal-title":"Leuk Res"},{"key":"R13-6-20241211","doi-asserted-by":"crossref","first-page":"60","DOI":"10.6004\/jnccn.2017.0007","article-title":"Myelodysplastic syndromes, version 2.2017, NCCN clinical practice guidelines in oncology","volume":"15","author":"Greenberg","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"key":"R14-6-20241211","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.leukres.2013.12.020","article-title":"Proposal for refining the definition of dysgranulopoiesis in acute myeloid leukemia and myelodysplastic syndromes","volume":"38","author":"Goasguen","year":"2014","journal-title":"Leuk Res"},{"key":"R15-6-20241211","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.leukres.2018.08.022","article-title":"Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDS","volume":"73","author":"Miyazaki","year":"2018","journal-title":"Leuk Res"},{"key":"R16-6-20241211","doi-asserted-by":"crossref","first-page":"121","DOI":"10.5144\/1658-3876.2011.121","article-title":"Outcome of allogeneic stem cell transplantation with a conditioning regimen of busulfan, cyclophosphamide and low-dose etoposide for children with myelodysplastic syndrome","volume":"4","author":"Al-Seraihy","year":"2011","journal-title":"Hematol Oncol Stem Cell Ther"}],"container-title":["Hematology\/Oncology and Stem Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658387620301734?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658387620301734?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ovid.com\/10.1016\/j.hemonc.2020.11.001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:41:07Z","timestamp":1787838067000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1016\/j.hemonc.2020.11.001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1016\/j.hemonc.2020.11.001","relation":{},"ISSN":["1658-3876"],"issn-type":[{"value":"1658-3876","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]}}}